Colorado State University
Fort Collins, Colorado, 80523, United States
Location status: Recruiting
NCT Number: NCT07816809
Bacteriophages are viruses that can selectively infect specific species and strains of bacteria. Some bacterial species in the human gut have been negatively associated with gut health and skin health. This study is designed to measure the efficacy of two different bacteriophage-based treatments for 4 weeks to improve gut and skin health. These treatments are bacteriophage that target specific strains of Escherichia coli and Staphylococcus Aureus.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Fort Collins, Colorado, 80523, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 x 106 Plaque Forming Units (PFU) of bacteriophage strains PBH34, CAH57, BFX121, and DNK95
Other names: MuniPhage
1 x 106 PFU of phage strains LG91, BD117, CD007, and PD23
Other names: RenuPhage
Rice maltodextrin
Time frame: 4 weeks
The gastrointestinal symptom rating scale is a widely used tool for measuring gastrointestinal symptoms across five domains.
Contact information is provided by the study sponsor or research team.
Jenny Whittington, MS
CONTACT
Tiffany Weir, PhD
CONTACT
Colorado State University
Other
Phage-CLEAR: Phage-based Control and Limitation of Pathobionts for Microbiome Equilibrium and Resilience
Acronym: Phage-CLEAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05972291
Colonic Diseases, Colonic Diseases, Functional
Memphis, Tennessee, United States
View Trial DetailsNCT06937814
Bowel Movements, GI Issues
London, Ontario, Canada
View Trial DetailsNCT07453823
Gastrointestinal Microbiome (Focus), Gastrointestinal Symptoms
Cork, Blackpool, Ireland
View Trial DetailsNCT07421596
Digestive Health, Gastrointestinal Symptoms
San Francisco, California, United States
View Trial Details